NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company that entered the public markets in 2021 through a business combination with Big Rock Partners Acquisition Corp., a blank-check vehicle sponsored by Big Rock Partners LLC. The company operates in the pharmaceutical and critical-care sectors, with its pipeline centered on central nervous system disorders, including NRX-101 for bipolar depression and related indications. On October 11, 2024, NRXP filed an 8-K current report with the Securities and Exchange Commission under accession number 0001437749-24-031133. Sign up at SpacDesk for full filing history, deal timelines, and real-time data on NRXP and the broader SPAC universe.